Wakix(pitolisant)
Ozawade, Wakix (pitolisant) is a small molecule pharmaceutical. Pitolisant was first approved as Wakix on 2016-03-31. It has been approved in Europe to treat narcolepsy and obstructive sleep apnea. The pharmaceutical is active against histamine H3 receptor. In addition, it is known to target histamine H4 receptor, histamine H1 receptor, and histamine H2 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Wakix
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pitolisant hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| WAKIX | Harmony Biosciences Holdings | N-211150 RX | 2019-08-14 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| wakix | New Drug Application | 2024-06-27 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
PITOLISANT HYDROCHLORIDE, WAKIX, HARMONY | |||
| 2027-10-13 | ODE-331 | ||
| 2026-08-14 | ODE-255 | ||
| 2024-08-14 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
33 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | — | 1 | 1 | 1 | — | 3 |
| Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | — | — | — | 1 | — | 1 |
| Psychomotor agitation | D011595 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Disorders of excessive somnolence | D006970 | — | G47.1 | — | 3 | 14 | — | 1 | 18 |
| Sleepiness | D000077260 | — | R40.0 | — | 3 | 12 | — | 1 | 16 |
| Narcolepsy | D009290 | HP_0030050 | G47.4 | — | — | 7 | — | 2 | 9 |
| Cataplexy | D002385 | HP_0002524 | — | — | — | 5 | — | 1 | 6 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | 1 | 4 | — | — | 5 |
| Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | — | 1 | 4 | — | — | 5 |
| Apnea | D001049 | HP_0002104 | R06.81 | — | 1 | 3 | — | — | 4 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | 2 | — | — | 3 |
| Prader-willi syndrome | D011218 | Orphanet_739 | Q87.11 | — | 1 | 1 | — | — | 2 |
| Idiopathic hypersomnia | D020177 | — | G47.11 | — | — | 2 | — | — | 2 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 1 | 1 | — | — | — | 2 |
| Nervous system alcohol-induced disorders | D020268 | — | — | — | 1 | — | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | — | — | — | 1 |
| Myotonic dystrophy | D009223 | — | G71.11 | — | 1 | — | — | — | 1 |
| Autistic disorder | D001321 | HP_0000717 | F84.0 | — | 1 | — | — | — | 1 |
| Autism spectrum disorder | D000067877 | HP_0000729 | F84.0 | — | 1 | — | — | — | 1 |
| Pervasive child development disorders | D002659 | EFO_0003756 | F84 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 1 | — | — | — | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | — | 1 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | 1 | — | — | — | — | 1 |
| Alcoholic intoxication | D000435 | — | — | 1 | — | — | — | — | 1 |
| Alcohol drinking | D000428 | EFO_0004329 | — | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy rate | D018873 | — | — | — | — | — | — | 1 | 1 |
| Anhedonia | D059445 | — | R45.84 | — | — | — | — | 1 | 1 |
| Cognition | D003071 | EFO_0003925 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pitolisant |
| INN | pitolisant |
| Description | Pitolisant is an organochlorine compound. |
| Classification | Small molecule |
| Drug class | histamine H3 receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Clc1ccc(CCCOCCCN2CCCCC2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 362665-56-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL462605 |
| ChEBI ID | — |
| PubChem CID | 9948102 |
| DrugBank | DB11642 |
| UNII ID | 4BC83L4PIY (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 578 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
713 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use